Revenue
2022
2023
2024
2025
Solvonis Therapeutics plc (SVNS)
Price£0.00115Cached quote
Financial statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | £0 | £0 | £587,000 | £542,000 |
| Gross profit | N/A | £0 | £258,000 | £300,000 |
| Gross margin | N/A | N/A | 43.95% | 55.35% |
| Operating expenses | £3.6M | £41,000 | £213,000 | £238,000 |
| Operating income | −£5.7M | −£1.4M | −£3.1M | −£2.7M |
| Operating margin | N/A | N/A | −531.01% | −498.34% |
| EBITDA | −£5.7M | −£1.4M | −£2.9M | −£2.6M |
| EBITDA margin | N/A | N/A | −500.51% | −477.49% |
| Net income | −£5.7M | −£1.6M | −£3.1M | −£2.7M |
| Net profit margin | N/A | N/A | −531.52% | −499.08% |
| Basic EPSper basic share | -£0.00 | -£0.00 | -£0.03 | -£0.03 |
| Diluted EPSper diluted share | -£0.00 | -£0.00 | -£0.03 | -£0.03 |
Owners
Reported ownership